Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Multi-million-euro win in Spanish lottery in doubt due to oversight - 2‘Slender Man’ attacker back in custody. What we know about Morgan Geyser's disappearance and what happens next.
- 3A hospital discharged a woman in labor. This lawmaker wants change.
- 4Vinicultural Investigation: A Survey of \Enjoying Fine Vintages\ Wine sampling
- 5Vote In favor of Your Favored IT Administration
- Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
- The most effective method to Alter Your Savvy Bed for A definitive Rest Insight
- Haunting Giant Squid Surfaces in Japan and Devours Its Prey (Video)
- NASA Artemis II tracker: Crew less than 60,000 miles from moon ahead of Monday flyby
- Arctic sea ice hits lowest winter level as heat records are shattered worldwide
- EU chief urges Iran to free imprisoned protesters, lift internet ban
- Air New Zealand cuts flights and hikes fares as fuel prices surge
- Civilian toll mounts in Iran as war presses on
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
